Akorn Sues Fresenius Medical Over Terminated Merger Agreement
Akorn sues Fresenius Medical: US-based drug manufacturing company Akorn Inc. (NASDAQ:AKRX) has sued German-based Fresenius Kabi AG, a subsidiary of Fresenius Medical Care Ag (NYSE:FMS), in a Delaware court on Monday, citing that Fresenius failed ... [Read]
Shineco Stock Sets An Upward Tone; Investors Applauded Q2 Results
Shineco Inc (NASDAQ:TYHT) lost 86% of its stock price in the last three years; blamed mainly on lower than expected results. Following the considerable selloff and hitting the bottom of $1.34 last week, investors are ... [Read]
Imprimis Pharmaceuticals Shares Rallied On Glaucoma Drugs
Imprimis Pharmaceuticals Inc. (NASDAQ:IMMY) shares bounced as much as 22.61% in Tuesday’s trade, supported by the announcement that the company is now making two glaucoma drugs listed on the FDA’s Drug Shortage List. Despite the ... [Read]
Sorrento Therapeutics Higher on Bullish Reports
Sorrento Therapeutics (NASDAQ:SRNE) shares are rallying over the last three months, thanks to the company’s smart business strategies and advancements in its pipeline. Its shares spiked more than 20% in Monday trade and its volume ... [Read]
Sucampo Pharmaceuticals Shares have 157% Upside
Sucampo Pharmaceuticals (NASDAQ:SCMP) stock price rallied sharply in the last three months, surging more than 74%. Despite the recent rally, Sucampo Pharmaceuticals’ stock has strong upside potential, supported by its improving financial numbers and the ... [Read]
Aradigm Corporation Dropped More Than 30% Today, Here’s Why
Regardless of whether or not you are an Aradigm Corporation (NASDAQ:ARDM) shareholder, it is crucial that the entire marketplace becomes aware of the latest news surrounding the Hayward, California-based specialty pharmaceutical company. What’s Happened? Despite ... [Read]
Head-to-Head: Impax Laboratories VS. SCYNEXIS
Impax Laboratories (NASDAQ:$IPXL) and SCYNEXIS (NASDAQ:$SCYX) are both small-cap companies competing in the medical sector. So how do these two rivals stack up against each other? Let’s look at the numbers. Profitability Impax Laboratories has ... [Read]
Is Impax Laboratories a Buy At $16?
Impax Laboratories (NASDAQ:$IPXL) currently has a going rate of $20.75 per share. This could be a shaky proposition for some investors. However, there may be another way to get in on the drug manufacturer’s stock. ... [Read]
Impax Laboratories Inc: A Technical Snapshot
In the most recent session, shares of Impax Laboratories Inc. (NASDAQ:$IPXL) dropped -$0.83, a volatility of -3.87%. Prices recently reached $20.62 on a volume of 3,190,000. Some investors may value creating innovative and individual strategies ... [Read]
An Analysis of pSivida Corp.
Recently, pSivida Corp. (NASDAQ:$PSDV) has failed to live up to its previous stock prices. The current price stands -1.41% below the 20 day average. While the stock did recover partially over the 50 day moving ... [Read]